INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

A Multicenter Open-Label Study to Assess the Safety of a New Formulation of BLP25 Liposome Vaccine in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer

(2010) Charles Butts et al.   Clinical Lung Cancer

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

(2010) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer

(2010) Thomas E. Stinchcombe et al.   Journal of Thoracic Oncology

Asian Ethnicity Is a Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer (NSCLC) and Is Independent of Smoking Status

(2010) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era

(2010) Myung-Ju Ahn et al.   Journal of Thoracic Oncology

Japanese Ethnicity Compared with Caucasian Ethnicity and Never-Smoking Status Are Independent Favorable Prognostic Factors for Overall Survival in Non-small Cell Lung Cancer: A Collaborative Epidemiologic Study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry Databases

(2010) Tomoya Kawaguchi et al.   Journal of Thoracic Oncology

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

(2010) S Bafna et al.   ONCOGENE

Maintenance and Consolidation Therapy in Patients with Unresectable Stage III/IV Non-Small Cell Lung Cancer

(2010) N. Thatcher et al.   ONCOLOGIST

Evaluation on the incidence, mortality and tendency of lung cancer in China

(2010) Wanqing Chen et al.   Thoracic Cancer

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Systemic effects of local radiotherapy

(2009) Silvia C Formenti et al.   LANCET ONCOLOGY

Targeted therapies for non-small cell lung cancer

(2009) Wolfram C.M. Dempke et al.   LUNG CANCER

EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer

(2009) Meina Wu et al.   LUNG CANCER

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future

(2008) Chih-Hsin Yang   LUNG CANCER

Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer

(2008) R E Roses et al.   ONCOGENE